Jeremy Thomas1, Andrew Hanby2, Sarah E Pinder3, Graham Ball4, Gill Lawrence5, Anthony Maxwell6, Matthew Wallis7, Andrew Evans8, Hilary Dobson9, Karen Clements10, Alastair Thompson11. 1. Department of Pathology, Western General Hospital, Edinburgh EH4 2XU, UK. Electronic address: jeremy.thomas@nhslothian.scot.nhs.uk. 2. Department of Histopathology, Algenon-Firth Building, Leeds General Infirmary, Gt George Street, Leeds, UK. Electronic address: a.m.hanby@leeds.ac.uk. 3. Research Oncology, Division of Cancer Studies, King's College London, 3rd Floor, Bermondsey Wing, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK. Electronic address: sarah.pinder@kcl.ac.uk. 4. Van Geest Cancer Centre, School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, UK. Electronic address: graham.balls@ntu.ac.uk. 5. West Midlands Knowledge and Intelligence Team, Public Health England, 1st Floor, 5 St Philip's Place, Birmingham B3 2PW, UK. Electronic address: g.lawrence@nhs.net. 6. Nightingale Centre and Genesis Prevention Centre, University Hospital of South Manchester, Southmoor Road, Manchester M23 9LT, UK. Electronic address: anthony.maxwell@manchester.ac.uk. 7. Cambridge Breast Unit and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Box 97, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0QQ, UK. Electronic address: matthew.wallis@addenbrookes.nhs.uk. 8. Department of Radiology, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK. Electronic address: a.z.evans@dundee.ac.uk. 9. West of Scotland Breast Screening Service, Stock Exchange Court, 77 Nelson Mandela Place, Glasgow G2 1QT, UK. Electronic address: hilary.dobson@ggc.scot.nhs.uk. 10. West Midlands Cancer Screening QA Reference Centre, Public Health England, 1st Floor, 5 St Philip's Place, Birmingham B3 2PW, UK. Electronic address: karen.clements@phe.gov.uk. 11. Department of Surgical Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address: a.m.thompson@dundee.ac.uk.
Abstract
BACKGROUND: The Sloane Project is the largest prospective audit of ductal carcinoma in situ (DCIS) worldwide, with over 12,000 patients registered between 2003 and 2012, accounting for 50% of screen-detected DCIS diagnosed in the United Kingdom (UK) over the period of accrual. METHODS: Complete multidisciplinary data from 8313 patients with screen-detected DCIS were analysed for surgical outcome in relation to key radiological and pathological parameters for the cohort and also by hospital of treatment. Adverse surgical outcomes were defined as either failed breast conservation surgery (BCS) or mastectomy for small lesions (<20mm) (MFSL). Inter-hospital variation was analysed by grouping hospitals into high, medium and low frequency subgroups for these two adverse outcomes. RESULTS: Patients with failed BCS or MFSL together accounted for 49% of all mastectomies. Of 6633 patients embarking on BCS, 799 (12.0%) required mastectomy. MFSL accounted for 510 (21%) of 2479 mastectomy patients. Failed BCS was associated with significant radiological under-estimation of disease extent and MFSL significant radiological over-estimation of disease extent. There was considerable and significant inter-hospital variation in failed BCS (range 3-32%) and MFSL (0-60%) of a hospital's BCS/mastectomy workload respectively. Conversely, there were no differences between the key radiological and pathological parameters in high, medium and low frequency adverse-outcome hospitals. CONCLUSIONS: This evidence suggests significant practice variation, not patient factors, is responsible for these adverse surgical outcomes in screen-detected DCIS. The Sloane Project provides an evidence base for future practice benchmarking.
BACKGROUND: The Sloane Project is the largest prospective audit of ductal carcinoma in situ (DCIS) worldwide, with over 12,000 patients registered between 2003 and 2012, accounting for 50% of screen-detected DCIS diagnosed in the United Kingdom (UK) over the period of accrual. METHODS: Complete multidisciplinary data from 8313 patients with screen-detected DCIS were analysed for surgical outcome in relation to key radiological and pathological parameters for the cohort and also by hospital of treatment. Adverse surgical outcomes were defined as either failed breast conservation surgery (BCS) or mastectomy for small lesions (<20mm) (MFSL). Inter-hospital variation was analysed by grouping hospitals into high, medium and low frequency subgroups for these two adverse outcomes. RESULTS:Patients with failed BCS or MFSL together accounted for 49% of all mastectomies. Of 6633 patients embarking on BCS, 799 (12.0%) required mastectomy. MFSL accounted for 510 (21%) of 2479 mastectomy patients. Failed BCS was associated with significant radiological under-estimation of disease extent and MFSL significant radiological over-estimation of disease extent. There was considerable and significant inter-hospital variation in failed BCS (range 3-32%) and MFSL (0-60%) of a hospital's BCS/mastectomy workload respectively. Conversely, there were no differences between the key radiological and pathological parameters in high, medium and low frequency adverse-outcome hospitals. CONCLUSIONS: This evidence suggests significant practice variation, not patient factors, is responsible for these adverse surgical outcomes in screen-detected DCIS. The Sloane Project provides an evidence base for future practice benchmarking.
Authors: Maartje van Seijen; Esther H Lips; Alastair M Thompson; Serena Nik-Zainal; Andrew Futreal; E Shelley Hwang; Ellen Verschuur; Joanna Lane; Jos Jonkers; Daniel W Rea; Jelle Wesseling Journal: Br J Cancer Date: 2019-07-09 Impact factor: 7.640
Authors: Zoltan Szucs; James Joseph; Tim J Larkin; Bangwen Xie; Sarah E Bohndiek; Kevin M Brindle; André A Neves Journal: Breast Cancer Res Date: 2021-02-17 Impact factor: 6.466